The multiple sclerosis is a nervous system disease that affects the spinal cord and brain. It damages the myelin sheath, which is a term used to exemplify that materials which surrounds & protects human nerve cells. This damage blocks the messages between the brain & body and leads to the symptoms of multiple sclerosis. It affects women more than men. The disease occurs between age group of 20 to 40. It is mainly divided into four types: relapsing-remitting multiple sclerosis, progressive-relapsing multiple sclerosis, secondary-progressive multiple sclerosis and primary-progressive multiple sclerosis. Relapsing-remitting multiple sclerosis is most common form of the disease. Some of the key symptoms of multiple sclerosis include thinking & memory problems, problem in coordination, visual disturbances, and balancing of the body & muscle weakness.
According to study, “Multiple Sclerosis Drugs Market Global Report 2020-30” the key companies operating in the global multiple sclerosis drugs market are Bayer HealthCare, Pfizer, Inc., Biogen, Novartis, Roche, Merck & Co., Inc., GlaxoSmithKline, Acorda Therapeutics Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Actelion Pharmaceuticals (Johnson & Johnson), Betaseron, CinnoVex, Extavia, Rebif, EMD Serono (Merck KGaA), AbbVie, Inc., Tysabr. The key companies are rapidly growing their efforts to focus on innovative product launches to cater to the increasing demands for multiple sclerosis drugs. The multiple sclerosis requires an enduring treatment that increases the overall cost of treating any patient. In order to offer better & effective treatment, companies are developing drugs precise to the treatment of multiple sclerosis.
Based on drug class, multiple
sclerosis drugs market is segmented as immunosuppressants, immunomodulators,
interferons and others. Based on route of administration, market is segmented
as injection (subcutaneous, intramuscular and intravenous) and oral. In
addition, based on distribution channel, market is segmented as retail
pharmacy, hospital pharmacy and online pharmacy.
The multiple sclerosis drugs market
is driven by rise in prevalence of multiple sclerosis. Apart from this, several
other factors for instance genetic & environmental are contributing to the
increasing incidence of multiple sclerosis. Prevalence of autoimmune diseases
such as type1 diabetes & certain infections, including the infectious
mononucleosis also lead to rising risk of multiple sclerosis. With the surging
incidence of this health condition, the demand for multiple sclerosis drugs
will increase considerably in upcoming years which will contribute to the
growth of this market size. However, high cost of drugs to treat multiple
sclerosis may impact the market. Moreover, growth in development of novel drugs
is a key trend for market.
Based on geography, the
North-American region holds major share in global multiple sclerosis drugs
market owing to rise in awareness about multiple sclerosis and its treatment in
the region. The Asian-Pacific and European regions are estimated to exhibit
substantial growth rate due to supportive health reimbursement policies over
the forecast period. It is expected that future of the global market will be
bright as a result of increase in distribution networks of pharmaceutical
companies during the forecast period. The global multiple sclerosis drugs
market was valued at US $20.83 billion in 2019 and it is likely to grow at a
CAGR of 5.20% and reach US $25.52 billion by 2023.
For More Information, Click on the Link Below:-
Global
Multiple Sclerosis Drugs Market
Related Reports:-
Global
Multiple Sclerosis Drugs Market Status and Future Forecast 2015-2025
Global
Multiple Sclerosis Drugs Market Analysis 2013-2018 and Forecast 2019-2024
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing &
Communications
No comments:
Post a Comment